ClinicalTrials.gg
RecruitingNCT06481228Updated Mar 2, 2026

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

An interventional study of CAR-T cells and Venetoclax in Philadelphia Positive Acute Lymphoblastic Leukemia and Acute Lymphoblastic Leukemia, Adult, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 6 open to participants now, 8 under way, none of them phase 3. Chimeric Antigen Receptor T-cells · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
Largest of 10
82 · median 19
Started
2024
with 2 others
No phase
2 of 10
2 open now
Registered
7th of 10
by date
Lead sponsor
2 of 10
Institute of Hematology & Blood Diseases Hospital, China

Among the 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one has the largest planned enrollment, is one of 3 that started in 2024, is one of 2 with no phase, and was the 7th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

6 of the 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About Chimeric Antigen Receptor T-cells

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Chimeric Antigen Receptor T-cells in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

In recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory (R/R)B-ALL. The available data suggest that the advancement of immunotherapy from R/R field to the frontline setting may be an important approach to increase the depth of remission, which ultimately translates into a survival benefit. In this study, the investigators propose a treatment regimen using CAR-T cell therapy as a consolidation method for Ph+ ALL patients achieving complete remission (CR) with overembatinib, venetoclax and reduced-intensity chemotherapy, aiming to reduce the total cycles of chemotherapy and related toxicities, shorten length of hospitalization, and ultimately improve patients' survival and quality of life.The study endpoints include 2-year disease-free survival (DFS) rate, overall survival (OS) rate, event-free survival (EFS) rate, cumulative molecular remission rate, immune repertoire-minimal residual disease (MRD) remission rate, cumulative relapse rate, treatment-related toxicities, and quality of life. Additionally, an interim analysis will be conducted, with the 1-year DFS rate as the key index for this analysis.

Read the detailed description

The CAR-T cells were murine-derived second-generation CD19 CAR-T with a co-stimulation domain of 4-1BB, and the infusion dose was 1×10\^6/kg CAR+ cells in a single infusion.

03

Conditions studied

  • Philadelphia Positive Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia, Adult

Keywords

  • Ph-Positive Acute Lymphoblastic Leukemia
  • CAR-T cell
  • Venetoclax
  • olverembatinib
  • Newly Diagnosed
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged 18 years or older
  2. Newly diagnosed Philadelphia chromosome positive(either t(9;22) and/or BCR-ABL positive and/ or FISH positive) acute lymphoblastic leukemia
  3. CD19 expression on blasts
  4. Expected survival time greater than 3 months
  5. Adequate end organ function as defined by: Total ≤ 1.5 x (ULN); serum (ALT) and serum aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤5 x ULN if leukemic involvement of the liver is present; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related; normal electrolytes: Potassium ≥ LLN; Magnesium ≥ LLN; Phosphorus ≥ LLN; Cardiac color Doppler ultrasound ≥ 45%
  6. Subject has provided written prior to any screening procedure

Exclusion criteria

Exclusion Criteria:

  1. Lymphoid blast crisis of chronic myelocytic leukemia (CML)
  2. Previous or ongoing systemic anti-ALL therapy (including but not restricted to TKI and/or radiotherapy, except for appropriate pre-treatment)
  3. Patients with a history of myocardial infarction within 12 months or cardiac disorders disease (e.g., unstable angina, congestive heart failure, uncontrollable hypertension, uncontrollable arrhythmia, etc.)
  4. Uncontrolled active serious infections that could, in the investigator's opinion, potentially interfere with the completion of treatment
  5. Known seropositivity
  6. History of acute pancreatitis within 1 year of study screening or history of chronic pancreatitis
  7. Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL)
  8. Another diagnosed and treated within 5 years prior to diagnosis or previously diagnosed with another malignancy with evidence of residual disease. Patients with non-melanoma skin cancer or any type of carcinoma in situ that has been completely excised should not be excluded
  9. Female patients who are pregnant or breast feeding
  10. Clinical manifestations of active CNS or extramedullary involvement with ALL
  11. Poorly controlled diabetes, defined as glycosylated () values of >7.5%. Patients with preexisting, well-controlled diabetes are not excluded
  12. Any serious psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment
  13. Other conditions assessed by the investigators to be inappropriate for this study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    TKI Combined With Chemotherapy and Sequential CAR-T Cells

    Ph+ALL patients receiving CAR-T cells as consolidation therapy after achieving complete remission (CR) with overembatinib, venetoclax and reduced-intensity chemotherapy.

    Combination Product: CAR-T cells · Drug: Venetoclax · Drug: Olverembatinib

Interventions

06

What researchers measure

Primary outcomes

  1. Disease-free Survival (DFS)

    From CR1 to relapse, death from any cause or last follow-up

    Time frame: Up to 2 years post-registration

Secondary outcomes

  1. Overall survival (OS)

    From the date of registration to the date of death resulting from any cause.

    Time frame: Up to 5 years post-registration

  2. Event-free survival (EFS)

    From the date of registration to the date of induction failure, relapse, death from any cause, or last follow-up

    Time frame: Up to 5 years post-registration

  3. Cumulative rate of complete molecular response

    The cumulative rate of patients achieving complete molecular remission

    Time frame: Up to 1 year post-registration

  4. MRD-negative complete remission rate measured by NGS tracking clonal IG/TR rearrangements

    No clonal IG/TR rearrangements were detected by NGS

    Time frame: Up to 1 year post-registration

  5. Cumulative incidence of relapse (CIR)

    Calculated with the cumulative incidence method, with death in patients who had a complete hematologic response as a competing risk.

    Time frame: Up to 2 years post-registration

  6. The rate of adverse

    adverse events during the treatment

    Time frame: Up to 5 years post-registration

Other outcomes

  1. Interim analysis index

    It is planned to conduct one interim analysis in the study: when the median follow-up date of patients reaches 1 year, the Independent Data Monitoring Committee (IDMC) will perform a hypothesis test by comparing the 1-year disease-free survival (DFS) rate (the primary endpoint) of the trial group with the 70% 1-year DFS rate of the historical control. The alpha (α) spending function will be calculated using the O'Brien-Fleming method. If the DFS rate of the trial group is found to be significantly superior to that of the historical control in the interim analysis and achieves statistical significance at the nominal significance level αk, the trial may be terminated early. If no statistically significant difference is observed between the two groups in the interim analysis, the investigators will decide whether to continue the trial based on practical circumstances.

    Time frame: From enrollment to 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jun 2026, 23 months after the start.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 23 months is below that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
Jul 1, 2024
StartActual
Jun 4, 2024
Primary completionEst.
Jun 1, 2026
CompletionEst.
Jun 1, 2028
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06481228
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Jun 4, 2024
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Mar 2, 2026

Study contacts

Jianxiang Wang, Dr
Contact
wangjx@ihcams.ac.cn
86-22-23608451
Jianxiang Wang, Dr
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Chimeric Antigen Receptor T-cells · Olverembatinib

Start the discussion